2. Search Result
Search Result
Results for "

Primary Biliary Cholangitis

" in MedChemExpress (MCE) Product Catalog:

15

阻害剤およびアゴニスト

2

阻害性抗体

製品番号 製品名 Target 研究分野 構造式
  • HY-16737
    Elafibranor
    Maximum Cited Publications
    16 Publications Verification

    GFT505

    		 PPAR Metabolic Disease Inflammation/Immunology
    Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor
  • HY-19522
    Seladelpar
    1 Publications Verification

    MBX-8025; RWJ-800025

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar
  • HY-16643
    Linerixibat
    10+ Cited Publications

    GSK2330672

    		 Apical Sodium-Dependent Bile Acid Transporter Infection Metabolic Disease Inflammation/Immunology
    Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .
    Linerixibat
  • HY-160719
    2-octynoic acid-BSA

    		Peptide-Drug Conjugates (PDCs) Inflammation/Immunology
    NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research .
    2-octynoic acid-BSA
  • HY-P99404
    Quetmolimab

    E6011

    		 CXCR Inflammation/Immunology Cancer
    Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
    Quetmolimab
  • HY-134988
    EDP-305

    		FXR Phosphatase Cytochrome P450 Inflammation/Immunology
    EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
    EDP-305
  • HY-19522A
    Seladelpar sodium
    1 Publications Verification

    MBX-8025 sodium; RWJ-800025 sodium

    		 PPAR Metabolic Disease Inflammation/Immunology
    Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .
    Seladelpar sodium
  • HY-176510
    Elafibranor sulfoxide

    		PPAR Drug Metabolite Metabolic Disease Inflammation/Immunology
    Elafibranor (GFT505) sulfoxide is a sulfoxide metabolite of Elafibranor (HY-16737). Elafibranor is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor sulfoxide
  • HY-19522C
    Seladelpar (lysine dihydrate)
    1 Publications Verification

    MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
    Seladelpar (lysine dihydrate)
  • HY-16737R
    Elafibranor (Standard)

    GFT505 (Standard)

    		 PPAR Reference Standards Metabolic Disease Inflammation/Immunology
    Elafibranor (Standard) is the analytical standard of Elafibranor. This product is intended for research and analytical applications. Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor (Standard)
  • HY-19522B
    Seladelpar (lysine)
    1 Publications Verification

    MBX-8025 (lysine); RWJ-800025 (lysine)

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .
    Seladelpar (lysine)
  • HY-19522R
    Seladelpar (Standard)

    MBX-8025 (Standard); RWJ-800025 (Standard)

    		 PPAR Reference Standards Metabolic Disease
    Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar (Standard)
  • HY-P991554
    FFP-104

    		TNF Receptor Inflammation/Immunology
    FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
    FFP-104
  • HY-150787
    BMS-986339

    		FXR Cytochrome P450 Metabolic Disease
    BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .
    BMS-986339
  • HY-180131
    INVA8001

    ASB17061

    		 Proteasome Inflammation/Immunology
    INVA8001 (ASB17061) is a highly selective and orally active chymase inhibitor with IC50 values for human chymase and mouse mast cell proteinase 4 (mMCP-4) of 0.02 and 0.03 μM, respectively. INVA8001 exhibits IC50 values for bovine α-chymotrypsin and human cathesin G of 3.4 and 32.1 μM, respectively, and it shows over 1000-fold selectivity for other related serine proteases. INVA8001 inhibits mast cells in a mouse primary sclerosing cholangitis (PSC) model, improves bile duct pathology, and alleviates bile stasis, demonstrating anti-inflammatory and anti-fibrotic effects .
    INVA8001

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: